



30<sup>th</sup> April 2026

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001  
Scrip Code: 544250

The Secretary  
National Stock Exchange of India Limited  
C-1, Block G, Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra East, Mumbai - 400 051  
Symbol: SANOFICONR

**Sub.: Announcement under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release / Media Release**

Dear Sir/Madam,

We wish to inform you that the Board of Directors at its meeting held on Tuesday, 28<sup>th</sup> April 2026, *inter-alia* considered and approved the Unaudited Financial Results for the quarter ended 31<sup>st</sup> March 2026. In this regard, please find enclosed a press release for your information and record.

Thanking you.

Yours faithfully,  
For **Sanofi Consumer Healthcare India Limited**

**Nikunj Kumar Savaliya**  
**Company Secretary and Compliance Officer**  
**Membership No.: F7048**

**Press Release****Sanofi Consumer Healthcare India Limited reports****Q1'26 Revenue at ₹2,292 MN, Net Profit at ₹678 MN****Highlights for the Quarter Y-O-Y:**

- Revenue at ₹2,292 million, a growth of 33%
- Domestic Sales grew by 15.5%; aided by relaunches
- Export Sales grew by 144% due to low base
- Profit After Tax was up by 36%

**Mumbai, 28 April 2026:** Sanofi Consumer Healthcare India Limited (BSE:544250 | NSE: SANOFICONR) releases its financial results for the first quarter, demonstrating sustained growth momentum across key business segments. Revenue growth for the quarter stood at 33% year-on-year. Domestic sales grew by 15.5% aided by the relaunch of recalled products to the market. Profit after tax (PAT) for Q1 '26 reached ₹678 million, an increase of 36% on a year-on-year basis.

Commenting on the Q1'26 results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited**, said, *“Our performance this quarter reflects consistent, disciplined execution across our key markets. Domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results. Guided by science and driven by purpose, we remain committed to simplifying self-care and making it more accessible and effective for consumers”*

**About Sanofi Consumer Healthcare India Limited.**

Sanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on 1st June 2024. SCHIL now operates independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience in consumer healthcare, SCHIL aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care and Multivitamins. SCHIL's key brands include Allegra®, DePURA®, Avil® and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

**Contacts for Media Relations:**Clayton Dsouza | +91 9930011602 | [claytond@avianwe.com](mailto:claytond@avianwe.com)Shrutika Sukhi | +91 9167971057 | [shrutikas@avianwe.com](mailto:shrutikas@avianwe.com)